Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
GTG
vs
S
S&P/ASX 300
GTG
Over the past 12 months, GTG has outperformed S&P/ASX 300, delivering a return of 0% compared to S&P/ASX 300's 3% drop.
Stocks Performance
GTG vs S&P/ASX 300
Performance Gap
GTG vs S&P/ASX 300
Performance By Year
GTG vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Genetic Technologies Ltd
Glance View
Genetic Technologies Ltd is a molecular diagnostics company that develops and sells DNA-based tests, mainly for assessing a person’s inherited risk of disease. Its core products use genetic markers to help doctors and patients understand cancer risk, with a strong focus on breast and colorectal cancer. The company turns laboratory science into tests that can be ordered by healthcare providers and used to guide screening decisions. The company makes money by selling these tests and related testing services through healthcare channels and distribution partners. In practice, that means it works with clinics, physicians, laboratories, and other medical groups that order the tests for their patients. Its customers are the medical professionals and institutions that need a clearer view of inherited risk, rather than consumers buying a mass-market product. What makes Genetic Technologies different is its role in the healthcare value chain: it sits between genetic research and everyday medical decision-making. Instead of developing drugs or running hospitals, it packages genomic data into practical risk tests that can fit into preventive care. That gives it a business model tied to diagnostic adoption, clinical trust, and the use of genetics in routine screening.